These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18667743)

  • 41. Elevated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in patients with peripheral artery disease undergoing endovascular therapy.
    Kim GS; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    J Vasc Surg; 2015 May; 61(5):1223-30. PubMed ID: 25595408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
    Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
    J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?
    Bachorzewska-Gajewska H; Malyszko J; Sitniewska E; Malyszko JS; Pawlak K; Mysliwiec M; Lawnicki S; Szmitkowski M; Dobrzycki S
    Kidney Blood Press Res; 2007; 30(6):408-15. PubMed ID: 17901710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization.
    Ishibashi Y; Yamauchi M; Musha H; Mikami T; Kawasaki K; Miyake F
    Angiology; 2010 Nov; 61(8):724-30. PubMed ID: 20947866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contrast Volume to Cystatin C-Based Glomerular Filtration Ratio Predicts the Risk of Contrast-Induced Nephropathy After Cardiac Catheterization.
    Zhao JB; Liu Y; Wu DX; Chen JY; Duan CY; Chen SQ; Tan N
    Angiology; 2017 Mar; 68(3):207-215. PubMed ID: 27166381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of cystatin C concentrations between patients with chronic interstitial nephritis and glomerular diseases.
    Robles NR; Mena C; Chavez E; Bayo MA; Gonzalez Candia B; Cidoncha A; Lopez Gomez J; Cubero JJ
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28187233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions.
    Ribichini F; Gambaro G; Graziani MS; Pighi M; Pesarini G; Pasoli P; Anselmi M; Ferrero V; Yabarek T; Sorio A; Rizzotti P; Lupo A; Vassanelli C
    Clin Chem; 2012 Feb; 58(2):458-64. PubMed ID: 22166252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department.
    Kama A; Yılmaz S; Yaka E; Dervişoğlu E; Doğan NÖ; Erimşah E; Pekdemir M
    Acad Emerg Med; 2014 Jun; 21(6):615-22. PubMed ID: 25039544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
    Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
    Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
    Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
    J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
    Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
    Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points.
    Hoffmann U; Banas B; Fischereder M; Krämer BK
    Kidney Blood Press Res; 2004; 27(3):161-6. PubMed ID: 15256811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum NGAL, cystatin C and urinary NAG measurements for early diagnosis of contrast-induced nephropathy in children.
    Benzer M; Alpay H; Baykan Ö; Erdem A; Demir IH
    Ren Fail; 2016; 38(1):27-34. PubMed ID: 26584598
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cystatin C as biomarker of contrast-induced nephropathy in pediatric cardiac angiography.
    Osman Ö; Ayee Deniz O; Abdülkadir E; Cihat Ş; Hüsnü Oğuz S; Avse Banu Ç
    Turk J Med Sci; 2014; 44(2):178-85. PubMed ID: 25536721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
    Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
    J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
    Briguori C; Visconti G; Ricciardelli B; Condorelli G;
    EuroIntervention; 2011 Apr; 6(9):1117-22, 7. PubMed ID: 21518686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
    Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
    Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Double-blinded, randomized controlled trial of N-acetylcysteine for prevention of acute kidney injury in high risk patients undergoing off-pump coronary artery bypass.
    Song JW; Shim JK; Soh S; Jang J; Kwak YL
    Nephrology (Carlton); 2015 Feb; 20(2):96-102. PubMed ID: 25384603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.